CriticalAntiviral for systemic use, HIV-1 protease inhibitor; used only with a pharmacokinetic booster (ritonavir or cobicistat)×Class Ia antiarrhythmic (sodium channel blocker with intermediate kinetics)
Updated · Methodology
Mechanism
The liver clears quinidine mainly through the enzyme CYP3A4, and quinidine levels rise, for example, with ketoconazole, probably because of competition for this pathway (quinidine label, US Food and Drug Administration, FDA). Darunavir is taken only with a booster, ritonavir or cobicistat. In this regimen it slows the clearance of drugs that depend on CYP3A and also inhibits CYP2D6 (darunavir summaries of product characteristics, SmPC, European Medicines Agency, EMA). The pair has not been studied, but levels of quinidine and other antiarrhythmics are expected to rise (darunavir SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS, and EMA). Quinidine prolongs the corrected QT interval (QTc) in a dose-related way. The risk of torsade de pointes is higher with high quinidine blood levels, slow heart rate and low potassium, magnesium or calcium (quinidine FDA label). Quinidine is therefore on the list of drugs whose high levels can be life-threatening and which are contraindicated with darunavir (darunavir SmPC, EMA).
Symptoms
Prolongation of the corrected QT interval (QTc) itself causes no symptoms and shows only on the electrocardiogram (ECG). Ventricular arrhythmias cause palpitations, dizziness and fainting. Life-threatening torsade de pointes, frequent extrasystoles, ventricular tachycardia, ventricular flutter and ventricular fibrillation have been reported with quinidine (quinidine label, US Food and Drug Administration, FDA). Besides arrhythmias, too much quinidine causes low blood pressure, vomiting, diarrhoea, tinnitus, high-frequency hearing loss, vertigo, blurred and double vision, sensitivity to light, headache, confusion and delirium (quinidine FDA label).
Management
The combination is contraindicated. Quinidine is on the contraindication list of darunavir boosted with either ritonavir or cobicistat, including the fixed-dose darunavir/cobicistat tablet (darunavir and darunavir/cobicistat summaries of product characteristics, SmPC, European Medicines Agency, EMA; darunavir SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In the US, the ritonavir contraindications apply to darunavir with ritonavir, and quinidine is among them by name (darunavir and ritonavir labels, US Food and Drug Administration, FDA). Amiodarone, dronedarone, ivabradine and ranolazine are also contraindicated with darunavir. Use disopyramide, flecainide, mexiletine, propafenone and systemic lidocaine with caution and, where possible, monitor their blood levels (darunavir SmPC, AEMPS). Check the full prescribing information for interactions before and during darunavir treatment (darunavir/cobicistat FDA label). The corrected QT interval (QTc) on the electrocardiogram (ECG) predicts quinidine-induced ventricular arrhythmias better than the quinidine blood level (quinidine FDA label). If the patient has nevertheless taken both drugs and develops polymorphic ventricular tachycardia, including torsade de pointes, with unstable haemodynamics, stop quinidine and perform immediate cardioversion or overdrive pacing. Look for low potassium, magnesium and calcium and correct them (quinidine FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Norvir (ritonavir) prescribing information (2026)– AbbVie. NORVIR (ritonavir) tablets, oral solution, oral powder. Prescribing information, DailyMed setid 2849298e-de6e-47bb-8194-56e075b33fc3, sections 4 and 7.2
- FDA: Prezista (darunavir) prescribing information (2025)– FDA, DailyMed, setid 814301f9-c990-46a5-b481-2879a521a16f, SPL 08/2025 (Revised 03/2023), sections 4 and 7 (Table 10)
- EMA: Ficha técnica: Darunavir (Prezista, EU/1/06/380), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 106380007 (EU/1/06/380), secciones 4.3 y 4.5, consultado 10/2026
- FDA: Quinidine Sulfate Tablets USP (quinidine sulfate) prescribing information (2023)– FDA, DailyMed setid b0d6341b-d880-4f0b-8844-bc788c03004a (Epic Pharma), revisión 11/2023, secciones Clinical Pharmacology, Warnings, Precautions (Drug Interactions) y Overdosage
- EMA: Ficha técnica: Darunavir/cobicistat (EU/1/14/967), sección 4.5 (2026)– EMA, Rezolsta 800 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114967001, consultada 10/2026, secciones 4.3 y 4.5
- AEMPS: Ficha técnica: Darunavir (Darunavir Aurovitas, nº registro 84835), sección 4.5 (2023)– AEMPS, CIMA, nº registro 84835, revisión 09/2023, secciones 4.3 y 4.5
- FDA: PREZCOBIX (darunavir and cobicistat) prescribing information (2026)– FDA, DailyMed setid 9c38fdb6-d0ba-4f16-a0e3-85d9ec334d9f (Janssen Products), revisión 02/2026 (versión 29), secciones 4, 6.2, 7.1 y 7.3